依库珠单抗成功逆转难治性移植后血栓性微血管病
Successful Reversal of Refractory Posttransplant Thrombotic Microangiopathy with Eculizumab.
作者信息
Chaudhary Satish, Sharma Reetesh, Gupta Saumya, Paikra Sita, Gupta Mohit, Upadhyay Bal K, Sharma Alok, Sethia Rajiv K
机构信息
Department of Nephrology and Kidney Transplant Medicine, Asian Institute of Medical Sciences, Faridabad, India.
Nephrology and Kidney Transplant Medicine, Dr. Lalpathlabs National Reference Laboratories, New Delhi, India.
出版信息
Indian J Nephrol. 2024 Mar-Apr;34(2):191-194. doi: 10.4103/ijn.ijn_345_22. Epub 2023 Apr 4.
Posttransplant thrombotic microangiopathy (PT-TMA) can be caused by calcineurin inhibitors (CNIs), ischemic injury, infections, or antibody-mediated rejection (ABMR). Delayed recognition can result in allograft loss. We describe the first reported case of successful reversal of refractory PT-TMA with eculizumab in India. It highlights the importance of prompt diagnosis and benefit from an early initiation of eculizumab therapy in refractory cases.
移植后血栓性微血管病（PT-TMA）可由钙调神经磷酸酶抑制剂（CNIs）、缺血性损伤、感染或抗体介导的排斥反应（ABMR）引起。诊断延迟可导致移植器官丧失。我们描述了印度首例使用依库珠单抗成功逆转难治性PT-TMA的报道病例。它强调了及时诊断的重要性以及在难治性病例中早期启动依库珠单抗治疗的益处。
Zotero 插件